PAREXEL Named 2014 Best Performing CRO in Taiwan for Drug Development and Healthcare Industry Leadership
Company recognized by Foundation of Medical Professionals Alliance in Taiwan
BOSTON, MA, and TAIPEI, Taiwan June 23, 2014 – PAREXEL International (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that it has been named the 2014 Best Performing CRO in Taiwan for its innovative drug development strategies and healthcare industry leadership. PAREXEL received the award in May from the Foundation of Medical Professionals Alliance in Taiwan (FMPAT) during the Taiwan Biotechnology Trend and Challenges conference.
“PAREXEL applies its scientific expertise and innovative approaches to reducing clinical trial complexity to help create greater opportunities for clinical research in Taiwan and across the region,” said Albert Liou, PAREXEL Vice Chairman, Asia Pacific. “We appreciate this recognition of our ongoing commitment to simplifying drug development for our customers and supporting their efforts to prevent and cure disease.”
Since 1999, PAREXEL has provided drug developers in Taiwan with a broad range of clinical research and consulting services, as well as innovative technology solutions. Two years ago, the Company formed an alliance with National Taiwan University Hospital to strengthen its ability to meet customer demand for end-to-end services in this rapidly growing market.
“PAREXEL has a strong presence to support both international, multi-center trials that include APAC as well as region and country-specific needs,” said Mark A. Goldberg, M.D., President and Chief Operating Officer, PAREXEL. “With 4,400 employees in 23 locations across 12 countries in the region, PAREXEL offers an unparalleled infrastructure to support customers across the entire development continuum.”
Founded in 1992, FMPAT has united medical and health professionals, and devoted itself to the promotion of health and dignity of society and citizens in Taiwan. The foundation is a pioneer in clinical research training programs, medical ethics and related policy advocacy. For more information, visit www.mpat.org.tw.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 75 locations in 50 countries around the world, and has 15,335 employees. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and “Your Journey. Our Mission.” are trademarks or registered trademarks of PAREXEL International
This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions, and to integrate newly acquired businesses including the recent acquisitions of LIQUENT, Inc. and HERON, Inc., or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 as filed with the Securities and Exchange Commission (SEC) on May 2, 2014, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.